Arctic Bioscience Operational Update Q4 2021
· Site feasibility for psoriasis phase IIb study with investigational medicinal product HRO350 complete · Project for new GMP manufacturing facility commenced · Full year 2021 revenues at NOK 22 million, a 7% increase from NOK 20.6 million in 2020 · Full year adjusted EBITDA of NOK -27.3 million vs NOK -20.5 million in 2020 · Year-end cash position remains solid at NOK 225.6m · Christer Valderhaug appointed new CEOArctic Bioscience is a biotech company founded on the unique benefits of herring roe - with a pre-commercial pharmaceutical business and a commercial nutraceutical